Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | -1,260.4% |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | -23,858.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | 11,443.4% |
| EPS Diluted | -1.03 | -0.86 | -74.32 | 1.07 |
| % Growth | -19.8% | 98.8% | -7,045.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |